Abstract
Background: Combination of different chemotherapy drugs and nanoparticles as a carrier has shown promising delivery system in cancer treatment. Doxorubicin is considered a potent anticancer drug. However, its off-target activities and possible side effects make its use limited. Recently, in the field of nanomedicine, different nanoconjugates have been developed as a unique platform for the delivery of therapeutic drugs.
Aims: The aim of the present study is to evaluate the best possible combination for efficient delivery of DOX with combination of gold, silver and zinc oxide nanoparticles to target site against carbon tetrachloride induced rat hepatotoxicity.
Methods: Effect of different conjugates administrated for 14 consecutive days was evaluated.
Results: In comparison to DOX, Au:DOX, ZnoO:DOX and Ag:DOX showed less sign of liver fibrosis as evaluated by serum enzymes and histopathological analysis. However, among all the conjugates, Ag: DOX conjugate showed the most significant results. The serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase values were (111.2 ± 38.21, 323.2 ± 46.88 and 303.6 ± 73.80 respectively) very close to control group (72.2 ± 19.41, 368 ± 59.78 and 259.4 ± 61.54 respectively).
Conclusion: Our results demonstrated that Ag: DOX may exhibit hepato-protective activity against CCl4 induced liver damage.
Keywords: Combination, drug delivery, nanoparticles, CCL4, hepatoprotective, nano conjugate, doxorubicin.
Current Drug Delivery
Title:In Vivo Evaluation of Inorganic Nanoparticle Complexes against CCL4 Induced Hepatotoxicity
Volume: 18 Issue: 8
Author(s): Rabia Tabbasam, Sana Khursid*, Yasmeen Ishaq and Arif Malik
Affiliation:
- Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore,Pakistan
Keywords: Combination, drug delivery, nanoparticles, CCL4, hepatoprotective, nano conjugate, doxorubicin.
Abstract:
Background: Combination of different chemotherapy drugs and nanoparticles as a carrier has shown promising delivery system in cancer treatment. Doxorubicin is considered a potent anticancer drug. However, its off-target activities and possible side effects make its use limited. Recently, in the field of nanomedicine, different nanoconjugates have been developed as a unique platform for the delivery of therapeutic drugs.
Aims: The aim of the present study is to evaluate the best possible combination for efficient delivery of DOX with combination of gold, silver and zinc oxide nanoparticles to target site against carbon tetrachloride induced rat hepatotoxicity.
Methods: Effect of different conjugates administrated for 14 consecutive days was evaluated.
Results: In comparison to DOX, Au:DOX, ZnoO:DOX and Ag:DOX showed less sign of liver fibrosis as evaluated by serum enzymes and histopathological analysis. However, among all the conjugates, Ag: DOX conjugate showed the most significant results. The serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase values were (111.2 ± 38.21, 323.2 ± 46.88 and 303.6 ± 73.80 respectively) very close to control group (72.2 ± 19.41, 368 ± 59.78 and 259.4 ± 61.54 respectively).
Conclusion: Our results demonstrated that Ag: DOX may exhibit hepato-protective activity against CCl4 induced liver damage.
Export Options
About this article
Cite this article as:
Tabbasam Rabia , Khursid Sana *, Ishaq Yasmeen and Malik Arif , In Vivo Evaluation of Inorganic Nanoparticle Complexes against CCL4 Induced Hepatotoxicity, Current Drug Delivery 2021; 18 (8) . https://dx.doi.org/10.2174/1567201818666210202105531
DOI https://dx.doi.org/10.2174/1567201818666210202105531 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Gene Therapy (Part II)
Current Gene Therapy Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Vitamin A: Modulating Effect on Breast Carcinogenesis
Current Nutrition & Food Science Meet the Editorial Board
Current Medicinal Chemistry Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Angiogenesis in Osteoarthritis
Current Rheumatology Reviews Vitamin-D Receptor (VDR) Gene Polymorphisms (TaqI, FokI) in Turkish Patients with Hashimoto’s Thyroiditis: Relationship to the Levels of Vit-D and Cytokines
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Current Cancer Drug Targets Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Targeting of Endothelial Dysfunction in Chronic Diabetic Complications
Recent Patents on Cardiovascular Drug Discovery Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets Single-cell Sequencing in the Field of Stem Cells
Current Genomics Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials
Current Women`s Health Reviews